Mature Results from the ECOG-E1405 Phase II Study of VcR-CVAD with Rituximab Maintenance for Untreated MCL


Mature Results from the ECOG-E1405 Phase II Study of VcR-CVAD with Rituximab Maintenance for Untreated MCL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Brad S Kahl, MD (1/17/13)

Kahl BS et al. Mature results from ECOG study E1405 — A Phase II study of VcR-CVAD with maintenance rituximab for previously untreated mantle cell lymphoma. Proc ASH 2012;Abstract 153.

Dr Kahl is Skoronski Chair of Lymphoma Research, Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.